David Dornan

David Dornan has extensive work experience in the field of oncology research. David is currently serving as the Chief Scientific Officer at Elevation Oncology since March 2022. Prior to this, they held the position of Independent Board Director at ReviR Therapeutics starting from January 2022.

From January 2021 to March 2022, David worked at Bolt Biotherapeutics, Inc. as the Chief Scientific Officer. Before that, they held multiple roles at the same company, including Senior Vice President of Research and Manufacturing from March 2019 to January 2021, and Senior Vice President of Research from November 2017 to March 2019.

From December 2016 to November 2017, David was the Director and Head of Oncology Research at Gilead Sciences. David also worked as a Senior Research Scientist II, Oncology at the same company from July 2012 to December 2016.

David's earlier experience includes roles at Genentech, where they served as a Senior Scientist and Scientist in the field of Molecular Diagnostics and Cancer Cell Biology. David managed a scientific group and led a multi-disciplinary team to deliver diagnostic strategies for pipeline molecules and approved therapies. David also worked as a Postdoctoral Research Fellow at Genentech.

Overall, David Dornan has a strong background in oncology research and has held various leadership positions in the industry.

David Dornan completed their Bachelor of Science degree in Biochemistry and Molecular Biology from the University of Strathclyde, graduating in 1999. Following this, they pursued their Ph.D in Molecular Oncology and Biochemistry at the University of Dundee, from 1999 to 2002.